Myongji Hospital
| Corea del Sud | Turchia | Austria | |
| Terapia ormonale | da $2,000 | da $406 | da $7,000 |
| Terapia mirata | da $5,500 | da $1,000 | da $12,000 |
| Rimozione di polipi gastrici | da $2,800 | da $754 | da $5,000 |
| Resezione gastrica | da $18,500 | da $12,000 | da $22,000 |
| Resezione della cistifellea | da $5,800 | da $4,050 | da $9,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Gastroenterologia. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Gastroenterologia e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento di procedure di Gastroenterologia.
Professor Kim Jong-yeon is a gastroenterologist at Myongji Hospital. He treats diseases of the esophagus, stomach, colon, and liver, including cirrhosis and hepatitis. He performs therapeutic endoscopy, such as endoscopic polypectomy. He also serves as Deputy Director of the International Healthcare Center.
He is a member of the Liver Failure Center. He works with teams in hepatology, liver cancer, and transplantation to provide coordinated care for advanced liver disease and for transplant candidates.
MD, Jeonbuk National University College of Medicine. Clinical Professor of Gastroenterology at Myongji Hospital. Member of the Korean Association of Internal Medicine, the Korean Society of Gastroenterology, and the Korean Society of Gastrointestinal Endoscopy. Former resident and fellow at Inje University Ilsan Paik Hospital.
Professor Park Jung-won is a leading Korean specialist in hepatocellular carcinoma with over 30 years of experience. He is the Director of the Liver and Liver Cancer Center and the Integrated Cancer Care Center at Myongji Hospital. He led Korea’s first HCC guidelines in 2003. He has also overseen their updates for about 20 years. His team validated proton beam radiotherapy for liver cancer, as published in the Journal of Hepatology. He has authored more than 200 SCI-indexed papers. He also helped lead global trials, including the 2025 CheckMate 9DW study, which showed improved outcomes with nivolumab plus ipilimumab for unresectable HCC.
MD/PhD, Seoul National University; Member, National Academy of Medicine of Korea; former President, Korean Liver Cancer Association; Chair, Korean HCC Guidelines Committee; Prime Minister’s and Health Minister’s commendations; Pfizer Medical Research Award and Roche Oncology Academic Award.